Who Paid My Doc
Joseph Garasic
Interventional Cardiology Boston, MA Medical Doctor
NPI 1154303808 CMS profile 278601
55 Fruit St, Cardiac Catheterization Lab Mgh, Boston, MA 02114
General payments
$151,858
Research payments
$134,185
Ownership & investment interest
$5,900
Research they led as principal investigator
$43,926
Through program year 2025, Joseph Garasic of Boston, MA is reported in the CMS Open Payments database as having received $151,858 across 123 general payments and $134,185 in research payments paid to them. Separately, studies naming them as principal investigator received $43,926 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $5,900 across 7 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
20 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $21,880 | 23 | |
| 2025 | Research | $37,125 | 5 | |
| 2024 | General | $14,850 | 14 | |
| 2024 | Research | $50,050 | 30 | |
| 2023 | General | $18,803 | 19 | |
| 2023 | Research | $4,600 | 36 | |
| 2022 | General | $41,398 | 24 | |
| 2022 | Research | $15,775 | 97 | |
| 2021 | General | $33,620 | 20 | |
| 2021 | Research | $17,035 | 104 | |
| 2020 | General | $10,000 | 14 | |
| 2020 | Research | $9,600 | 48 | |
| 2019 | General | $11,308 | 9 | |
| 2025 | Ownership | $380 | 1 | |
| 2024 | Ownership | $740 | 1 | |
| 2023 | Ownership | $740 | 1 | |
| 2022 | Ownership | $740 | 1 | |
| 2021 | Ownership | $1,100 | 1 | |
| 2020 | Ownership | $1,100 | 1 | |
| 2019 | Ownership | $1,100 | 1 |
Beside peers
- Joseph Garasic
- Interventional Cardiology median
- Middle half of Interventional Cardiology
- National median
In program year 2025, general payments to Joseph Garasic were reported at $21,880. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.
Show as a table
| Year | Joseph Garasic | Interventional Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $11,308 | $1,097 | $329–$3,048 | $163 |
| 2020 | $10,000 | $473 | $161–$1,480 | $114 |
| 2021 | $33,620 | $677 | $233–$1,827 | $132 |
| 2022 | $41,398 | $978 | $333–$2,724 | $149 |
| 2023 | $18,803 | $1,136 | $382–$2,986 | $160 |
| 2024 | $14,850 | $1,181 | $395–$3,326 | $164 |
| 2025 | $21,880 | $1,092 | $366–$3,019 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 64 billing codesPaid by Medicare
$102,102
Medicare patients
411
Services billed
1,070
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 75% | |
| Arthritis | 53% | |
| Heart failure | 49% | |
| Chronic kidney disease | 45% | |
| Diabetes | 43% | |
| Atrial fibrillation | 43% | |
| Depression | 27% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
3 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| LITFULO |
|
$2,625 | — | — |
| SKYRIZI |
|
$1,925 | — | — |
| RINVOQ |
|
$1,100 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
443 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Cardiology in Massachusetts
Eric Secemsky
Interventional Cardiology · Boston, MA
Darshan Doshi
Interventional Cardiology · Boston, MA
Charles Gibson
Interventional Cardiology · Boston, MA
Duane Pinto
Interventional Cardiology · Boston, MA
Robert Yeh
Interventional Cardiology · Boston, MA
Thomas Piemonte
Interventional Cardiology · Burlington, MA
Related records
Interventional Cardiology in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.